At a glance
ClinicalIndex Comparison RecordN/ACompleted· 155 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab
In Brief
An observational study for Rheumatoid Arthritis and 2 related conditions. Completed, enrolled 155 participants across 15 sites.
Detailed Summary
The purpose of this study is to assess whether or not adalimumab (Humira®) can influence pain medication in participants with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) with or without comorbidities, which do not constitute a contraindication for adalimumab as stated in the released summary of product characteristics. Therefore it shall be evaluated if pain medication which is used in these participants is changed, reduced or stopped due to adalimumab treatment.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesAustria
CollaboratorsRaffeiner GmbH
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
First PostedJan 2011
Primary CompletionJan 2013
TodayJul 2026
First PostedJan 10, 2011
Enrollment StartJan 1, 2011
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 15.5 years ago